Whitehawk Therapeutics (WHWK) Capital Expenditures (2016 - 2025)

Whitehawk Therapeutics (WHWK) has 10 years of Capital Expenditures data on file, last reported at -$552000.0 in Q3 2025.

• On a quarterly basis, Capital Expenditures rose 66.48% year-over-year to -$552000.0 in Q3 2025; TTM through Mar 2026 was $114000.0, a 93.21% decrease from a year earlier, with the FY2024 full-year figure at $1.7 million, up 419.31% from the prior year.
• Capital Expenditures for Q3 2025 stood at -$552000.0, down from $666000.0 in the prior quarter.
• Over the last five years, Capital Expenditures for WHWK reached as high as $2.0 million in Q4 2024 and fell as low as -$1.6 million in Q3 2024.
• Historically, Capital Expenditures has averaged $68687.5 across 5 years, with a median of -$45500.0 in 2022.
• Across the five-year window, Capital Expenditures sank 758.55% in 2021 and jumped 1784.17% in 2024, its largest moves.
• Year by year, Capital Expenditures stood at -$481000.0 in 2021, then jumped by 179.83% to $384000.0 in 2022, then plunged by 131.25% to -$120000.0 in 2023, then soared by 1784.17% to $2.0 million in 2024, then slumped by 127.31% to -$552000.0 in 2025.
• Per Business Quant data, the three most recent Capital Expenditures figures were -$552000.0 in Q3 2025, $666000.0 in Q2 2025, and -$114000.0 in Q1 2025.